Published

Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: American Journal of Preventive Medicine
Date: 2026-10-01
Source: Crossref
DOI: 10.1016/j.amepre.2026.108381
PubMed: 42092643

Authors

Yang Kevin H.Satybaldiyeva Nora Kepner Wayne Friedman Joseph Ping Siyuan Leas Eric C.

Watch author

Derived topics and classifications

psilocybin Microdosing Other

Citation graph

40 referenced DOIs found in stored source metadata. 2 indexed papers cite this DOI.

Open citation network

10.1177/0269881119857204 10.1016/j.drugpo.2019.11.008 10.1177/13872877251389608 10.1089/can.2023.0084 10.3390/businesses1030014 10.1080/02791072.2020.1718250 10.1038/s41398-022-02039-0 10.1016/j.neubiorev.2020.09.035 10.1001/jamapsychiatry.2025.0044 10.1186/s12954-019-0308-4 10.1177/0269881120953994 10.1177/02698811231190865

Indexed papers citing this DOI

Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults2026-10-01 Psilocybin and Mental Health Outcomes: Scoping Review with ☸️SAIMSARA2026-06-15

Related papers

A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older AdultsClinicalTrials.gov · 2026-08-10 A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's DiseaseClinicalTrials.gov · 2026-06-08 Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin.ClinicalTrials.gov · 2026-07-28